Oak Thistle LLC Sells 1,427 Shares of Insulet Co. (NASDAQ:PODD)

Oak Thistle LLC lessened its holdings in Insulet Co. (NASDAQ:PODD) by 30.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,323 shares of the medical instruments supplier’s stock after selling 1,427 shares during the period. Oak Thistle LLC’s holdings in Insulet were worth $570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Wolff Wiese Magana LLC lifted its holdings in Insulet by 117.3% during the 1st quarter. Wolff Wiese Magana LLC now owns 302 shares of the medical instruments supplier’s stock worth $52,000 after purchasing an additional 163 shares during the last quarter. Diversified Trust Co bought a new position in Insulet during the first quarter worth about $820,000. Sunbelt Securities Inc. acquired a new stake in Insulet in the 1st quarter worth about $29,000. Congress Asset Management Co. MA boosted its holdings in Insulet by 31.2% in the 1st quarter. Congress Asset Management Co. MA now owns 39,595 shares of the medical instruments supplier’s stock valued at $6,787,000 after purchasing an additional 9,426 shares during the period. Finally, Banque Cantonale Vaudoise grew its position in shares of Insulet by 79.1% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,614 shares of the medical instruments supplier’s stock worth $1,305,000 after purchasing an additional 3,362 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PODD. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a research note on Tuesday, May 7th. Jefferies Financial Group upped their price objective on Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Barclays dropped their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Finally, Redburn Atlantic began coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $239.18.

Insulet Trading Down 2.8 %

Shares of NASDAQ:PODD traded down $5.64 during trading on Monday, reaching $196.16. The stock had a trading volume of 696,571 shares, compared to its average volume of 877,681. The firm’s fifty day moving average is $184.23 and its 200 day moving average is $186.27. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $293.64. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of 59.44, a P/E/G ratio of 3.63 and a beta of 1.16.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. Insulet’s revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.23 earnings per share. As a group, equities analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the transaction, the director now owns 42,586 shares in the company, valued at $7,703,807.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Insulet news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at $2,737,431.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the sale, the director now owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The disclosure for this sale can be found here. Insiders have sold a total of 13,931 shares of company stock valued at $2,636,286 over the last ninety days. 0.47% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.